Phosphoinositide-3-kinase/protein-kinaseB/mammalian target of rapamycin (PI3K/AKT/mTOR) signalling plays an important role in breast cancer (BC). Its interaction with estrogen receptor (ER) signalling becomes more complex and inter-dependent with acquired endocrine resistance.
Introduction
Around 80% of breast cancers (BCs) express estrogen receptor alpha (ER) and depend on estrogen (E) to grow. Strategies to target ER activity include depriving the hormone dependent tumour cells of E by the use of aromatase inhibitors (AI) (1) or the use of anti-estrogens such as tamoxifen or fulvestrant, both of which compete with E for the ER. Despite the efficacy of these agents, many tumours exhibit de novo or develop acquired mechanisms of resistance.
De-regulated signalling through the PI3K/AKT/mTOR pathway is a feature of most types of cancer cells (2) and has been linked to endocrine resistant BC (3) (4) (5) . Activation of PI3K/AKT occurs via gain-of-function mutations in the catalytic domain of PI3K (PIK3CA) and the regulatory subunit p85α (PIK3R1), amplification of PIK3CA, PIK3CB and PDK1; or by reduced expression of phosphatase-and-tensin-homolog-deleted on chromosome ten (PTEN), an endogenous inhibitor of the PI3K/AKT pathway (6) . Furthermore, mutation and amplification of It is clear, that the ER can become involved with the PI3K/AKT/mTOR pathway in BC cells, with evidence for both genomic and non-genomic cross-talk between this signalling pathway and ER accounting for endocrine resistance (7) (8) (9) . Growth factor mediated activation of AKT can potentiate ER classical transcriptional activity via phosphorylation at serine 167 in the AF1 domain leading to ligand-independent transactivation (10) (11) (12) . Similarly, elevated levels of AKT have been shown to change the genome-wide binding pattern of ER, effectively altering the ERprogram (13) . These bi-directional interactions between hormonal and kinase signalling pathways create self-reinforcing synergistic loops that potentiate pro-survival signals and may allow BC cells to escape normal endocrine responsiveness.
Targeting the PI3K/AKT/mTOR pathway in association with endocrine therapy has seemed a sensible strategy to explore. However, blockade of a single protein in a complex signalling cascade is unlikely to provide total or prolonged growth inhibition. An important negative feedback loop exists downstream in the PI3K/AKT/mTOR pathway that may limit the effectiveness of mTOR inhibitors in BC. The mTOR activated kinase, S6K1, phosphorylates and destabilises the IRS1 and IRS2 proteins in insulin-like growth factor (IGF) responsive cells (14) .
In these cells, mTORC1 inhibition can lead to a reduction in S6K1 activity, which in turn allows IRS1/2 expression to be increased with associated enhanced activation of IGFR1-dependent AKT activity. Concern has been raised that activation of this negative feedback loop may overcome the anti-tumour activity of mTORC1 blockade and limit the effectiveness of rapamycin analogues (14, 15) .
In recent years, it has been suggested that direct blockade of AKT in combination with endocrine therapy, may provide a better rationale for treatment of endocrine resistant BC, impacting on both cell survival/apoptosis and ER ligand-independent signaling. A novel pan-AKT kinase catalytic inhibitor (AZD5363) has been developed and shown to inhibit the growth of a range of human tumor xenografts, either as monotherapy or in combination with HER2 inhibitors or with docetaxel (16). A recent study has also reported that combinations of AKT and IGF-1R/InsR inhibitors can be effective in the treatment of hormone-independent ER+ BC (17).
On the basis of these data, AZD5363 is currently being investigated in phase I clinical trials. most widely used approaches to endocrine therapy in the clinic, namely E-deprivation, tamoxifen, fulvestrant and AI in pre-clinical models of endocrine sensitive and resistant ER+ BC, as well as in a patient-derived xenograft (PDX) model of ER+ BC resistant to E-deprivation..
Material and methods

Antibodies and reagents
Primary antibodies against phospho-AKT Ser473 , phospho-AKT Thr308 , total-AKT, phospho- , total-Rb, phospho-RAF Ser259 , phospho-RAF Ser338 , total-RAF, phospho-PRAS40 Thr246 , total-PRAS40, Cyclin D1, Cyclin D3, total-ERK1/2, 14-3-3 were purchased from Cell Signalling
Technology, UK; total-IGF1R, cleaved-PARP, total-ERα and total-ERBB3 were purchased from Santa Cruz; phospho-ERK1/2 and Actin from Sigma; GAPDH (Abcam); PgR (Novocastro or Dako); IRS-1 and total-ERBB2 (Millipore); IRS-2 (Upstate) and finally total-ERBB4 (Neomarkers). Secondary antibodies (anti-mouse and anti-rabbit horseradish peroxidase) were obtained from Dako or Cell signalling. Antibodies used for chromatin immunoprecipitation were purchased from Santa Cruz: ERα clone HC20 and CBP clone A22. 17-β-estradiol and 4-hydroxytamoxifen (4-OHT) were purchased from Sigma-Aldrich; fulvestrant (ICI182780), letrozole and exemestane from Tocris Bioscience; AZD5363 was synthesised and supplied by AstraZeneca UK.
Tissue culture
Human BC cell lines MCF7, T47D, ZR75.1 and HCC1428 were obtained from the American red-free RPMI1640 medium supplemented with 10% fetal bovine serum and 1nM estradiol (E2).
All cell lines were banked in multiple aliquots to reduce the risk of phenotypic drift and identity confirmed using iPLEX-pro (Agena Bioscience). LTED cells modeling resistance to an AI were derived from all four parental cell lines by long-term culture in the presence of RPMI1640 medium containing 10% dextran charcoal stripped serum (DCC), as described previously (18).
The 1%MCF7 and TamR cell lines were cultured in DMEM/F-12 medium, as previously stated (19). MCF7-2A and BT474-A3 cells stably expressing CYP19 (AROM) were derived from parental MCF7 and BT474 cells, respectively and were maintained in phenol red-free RPMI1640 medium containing 10% fetal bovine serum supplemented with 1nM E2 and 1mg/ml G-418 (Sigma-Aldrich, UK) (20). All cell lines were stripped of steroids for 48-72-hours prior to the start of experiments.
Proliferation and colony formation assays
Cells were seeded in 10% DCC into 96-well tissue culture plates and allowed to acclimatize overnight. Monolayers were then treated with RPMI1640 + 10% DCC containing increasing concentrations of AZD5363, with or without the presence of 0.01nM of E2. In order to assess the effects of AZD5363 in combination with endocrine agents, cells were maintained in the presence of GI 50 values of AZD5363 along with increasing concentrations of endocrine agent 4-OHT, fulvestrant or anastrozole. The medium was replaced after 3-days and cells were cultured for a total of 6-days. Each experiment was performed at least 3 times with 8 replicates per treatment. Cell viability was determined using the CellTitre-Glo® Luminescent Cell Viability Assay (Promega), according to the manufacture's protocol. Values were expressed as % viability relative to the untreated control.
For the colony formation assays, cells were seeded into 6-well plates and allowed to acclimatise for 24-hours. Subsequently, cells were treated with the drug combinations indicated, every 3-4 days, for the duration of 14-days until colonies were evident. Cells were then fixed using icecold methanol and stained using 0.5% w/v crystal violet in 90% H 2 0/10% methanol.
Drug interaction analysis
To determine the nature of the interaction between AZD5363 and endocrine agents, combination studies were carried out using Chou and Talalay's constant ratio combination model (21). Cells were treated with increasing doses of AZD5363 alone, endocrine agent alone, or an equipotent combination of AZD5363 and endocrine agent for 6 days. The GI 50 for each drug alone was used to define the ratio of equipotent doses and serial dilutions of the combinations used. Interactions were calculated using Calcusyn software (BIOSOFT), based on the combination index (CI) equation of Chou and Talalay. The CIs for a growth inhibition of 50%, 75%, and 90% were obtained using mutually non-exclusive Monte Carlo CI simulations. Drug interaction was scored using the CI so that: CI=1 is additive, CI <1 is synergistic, CI >1 is antagonistic.
Transcriptional assays
Cell lines were seeded in 24-well plates in 10% DCC medium and left to acclimatize for 24-hours, following transfection with Fugene 6 at a ratio of 6:1 (Promega) with 0.1μg of estrogen response element linked luciferase (EREIItkluc) and 0.1μg of β-galactosidase (pCH110) reporter constructs. The following day, cells were treated with the drugs combinations specified and left for 24h. Luciferase (Promega) and β-galactosidase (GalactoStar, Applied Biosystems) activity were measured using a luminometer. Each experiment was performed 3 times with 3-4 replicates per treatment.
Real-time quantitative PCR
mRNA from treated cells was extracted with RNeasy Mini Kit (Qiagen), as per the manufacturer's instructions, and quantification performed using the Agilent 2100
Bioanalyzer (Expert Software version B.02.03) with RNA Nano LabChip Kits (Agilent Technologies). Total RNA was reverse transcribed using SuperScript III (Invitrogen) and random primers, in accordance with the manufacturer's instructions. cDNA was subjected to quantitative PCR using 10ng of cDNA in triplicate using the ABI Perkin-Elmer Prism 
Western blotting
Cells were seeded into dishes and allowed to attach overnight. Monolayers were treated with the desired drug combinations for the required length of time. Whole-cell extracts were generated, as described previously (18). For the xenograft samples, tumours were lysed on ice, homogenized and sonicated. The resulting protein fraction was subjected to western blotting as previously described (18). The numerical data for each biomarker was determined using Genetools software and normalized to GAPDH control.
Cell cycle analysis
Cells were seeded into 10cm dishes and 24-hours later treated with the drug combinations indicated for 48-hours. Cells were fixed 90% ethanol and stained with propidium iodide. Cell cycle analysis was carried out using fluorescence-activated-cell sorting (FACS).
Gene expression data and microarray analysis
Gene expression analysis was performed in triplicate using RNA derived from MCF7 and their LTED derivatives after treatment with or without AZD5363 for 24-hours. mRNA extraction and quantification was performed, as previously stated. The 12 RNA samples were amplified, manufacturer's instructions (Illumina). Raw expression data were extracted using GenomeStudio (www.illumina.com) software; the data were then transformed and normalized using variancestabilizing transformation and robust spline normalization method in the Lumi package in R (http://www.bioconductor.org) (Accession number: GSE69893). Probes for which expression levels were not reliably detected in one of the samples (detection p.value > 0.01) were filtered, the remaining differentially expressed genes were identified by using the Class Comparison (http://linus.nci.nih.gov/BRB-ArrayTools.html) using the thresholds of FDR < 5%. The significantly expressed gene lists were subject to further pathway analysis using Ingenuity Pathway Analysis (IPA) to identify altered pathways due to the AZD5363 treatment and the altered pathways with p-value <0.05 were considered as significant.
Human tumour xenografts
In vivo efficacy studies were performed in 8-12-week old female Swiss nude mice implanted with the PDX HBCx22OvaR, as previously described (22), in accordance with the French Ethical Committee. Firstly, a pharmacodynamic (PD) study was performed for 4-days to assess biomarker changes with samples removed 2 and 4-hours post-treatment.
Between 5 and 7 mice were included in each group. Secondly, a long-term study to assess changes in tumour volume and progression over 90-days was initiated. In order, to address the ability of the combination to delay tumour progression, mice were followed for a further 40 days post-drug withdrawal. The treatment groups received AZD5363 solubilized in a 10% DMSO 25% w/v Kleptose HPB (Roquette) buffer by oral gavage, or fulvestrant suspended in corn oil by subcutaneous injection into the flank. For the combination groups, fulvestrant was dosed 2-hours before AZD5363. The control groups received both vehicles.
In the combination study, treatments were started when tumors reached a volume of 40-65 mm 3 . Each group included between 11 and 13 xenografts. Because the variance in mean tumour volume data increases proportionally with volume (and is therefore disproportionate between groups), data were log-transformed to remove any size dependency before statistical evaluation. Tumor volumes were reported to the initial volume as relative tumor volume (RTV). Percent of tumor growth inhibition (TGI) was calculated at the end of treatments (day 88) as follow: (1-RTVtreated/ RTVcontrol) x100. Statistical significance was evaluated using a one-tailed, two-sample t-test.
Fluidigm Analysis
Tumour samples were homogenised and RNA was extracted as described above. cDNA was synthesised using a high-capacity cDNA reverse transcription kit (Applied Biosystems). ERdependent genes listed (AQP3 (Hs01105469_G1); AREG (Hs00950669_m1); BMF
(Hs01083036_s1); TFF3 (Hs00902278_m1) and ZEB1 (Hs00232783_m1)) were selected and analysis was performed using the Fluidigm Biomark System, as per manufacture's instructions (Fluidigm). Data was analysed using a Real-Time PCR analysis software (version 3. to vehicle control. Statistical analysis was subsequently performed using JMP 11.0 to determine significant changes with a p-value of < 0.05.
Results
Effect of AZD5363 on cell growth of endocrine sensitive and resistant BC cell lines
A panel of endocrine sensitive and resistant BC cell lines were assessed for their sensitivity to the AKT inhibitor AZD5363, a pyrrolopyrimidine-derived compound (Fig. 1A) . MCF7, ZR75, Combination of fulvestrant with AZD5363 also increased drug sensitivity by c.2-fold in MCF7 and 1%MCF7 and by c.10-fold in MCF7-LTED and TamR compared to fulvestrant alone. ZR75, T47D and their LTED derivatives showed no added benefit from the combination (Fig. 2B ).
Finally, we assessed the effect of the combination of AZD5363 with increasing doses of anastrozole in MCF7-2A and BT474-A3 cells. Here again, the combination of AZD5363 with anastrozole versus anastrozole alone was superior (c. 5-10 fold increase in sensitivity to anastrazole) (Fig. 2C ). These data were further confirmed using a colony formation assay as an orthogonal approach in MCF7 and MCF7-LTED cells (Fig. 2D ).
Subsequently, we conducted formal assessment of the interaction between 4-OHT, fulvestrant or anastrozole with AZD5363, using Calcusyn software (Supplementary Figure S2) . T47D-LTED and ZR75-LTED were precluded from this analysis, as they loose expression of ER. The combination of AZD5363 and 4-OHT was synergistic in MCF7, MCF7-LTED and 1%MCF7, with combination indices (CIs) < 1, at 50% and 75% growth inhibition. In contrast, AZD5363 plus 4-OHT showed added benefit only in T47D at 50% and 75% growth inhibition.
In contrast, ZR75 at 75% and 90% growth inhibition showed no added benefit (CI>1) (Supplementary Figure S2A) . Of particular note, total PRAS40 was suppressed in T47D and their LTED. Phosphorylation of 4EBP1, a downstream marker of the PI3K/AKT/mTOR pathway, was reduced in T47D, T47D-LTED and ZR75-LTED in response to AZD5363 either alone or in combination with endocrine therapy (Fig. 3B) . AZD5363 also reduced expression of pRAF (S259), most noticeably in MCF7, T47D and their LTED derivatives; in contrast, the TamR cell line showed an increase in pRAF (S338). We have previously shown that inhibition of AKT can increase ERK signalling (19), therefore we assessed the effect of AZD5363 on pERK1/2 and showed differential responses. In order to assess the effect of AZD5363 on cell cycle arrest and apoptosis, we investigated changes in protein expression of Cyclin D1/D3, Rb and induction of PARP cleavage (Fig. 3C ).
The combination of AZD5363 ± endocrine therapy caused a decrease in expression of phosphorylated Rb and cyclin D in the majority of cell lines tested, with a higher effect being observed in combination with fulvestrant. Furthermore, cell cycle analysis showed a significant reduction in S-phase in response to AZD5363 in MCF7 and MCF7-LTED (Supplementary Figure S3C) . Subtle increases in PARP-cleavage were evident in MCF7 although this did not appear specific to treatment. In contrast, T47D-LTED showed increases in PARP cleavage specifically in response to AZD5363 addition (Fig. 3C) .
In summary, these data show AZD5363 impedes downstream AKT signalling and reduces ERphosphorylation in a context specific manner, leading to an increase in cell cycle arrest.
The effect of AZD5363 alone or in combination with endocrine therapy on receptor tyrosine kinase activity and ER-transactivation
We further assessed the impact of AZD5363 on the expression and phosphorylation of receptor tyrosine kinases (RTKs) in the target cell lines (Fig. 4A) . Inhibition of AKT with AZD5363 resulted in upregulation and activation of RTKs, including EGFR, ERBB2, but also IRS2, which was cell line specific (Fig. 4A) . MCF7-LTED, ZR75 and most notably ZR75-LTED showed an increase in pEGFR; T47D and T47D-LTED showed an increase in pERBB2 and IRS2; TamR revealed increases pERBB3.
As cross talk between ER and RTK pathways is well documented (12), we assessed alterations in ER-mediated transactivation after perturbation with AZD5363 alone or in combination with 
transfected with an ERE-linked luciferase reporter construct and treated with E2, 4-OHT or fulvestrant ± AZD5363 (Fig. 4B ). AZD5363 showed a significant effect on ER transactivation of MCF7, MCF7-LTED and T47D when in combination with all endocrine agents. In contrast, in ZR75 the effect on ER transactivation was minimal, apart from when combined with fulvestrant.
TamR cells similarly showed minimal impact on ER-mediated transcription. Further analyses of the expression of a panel of endogenous E-regulated genes (TFF1, PGR and GREB1), showed that AZD5363 had a similar impact in keeping with the ERE-linked-luciferase assay with the exception of T47D, which showed an increase in the expression of TFF1 when treated with AZD5363 but a decrease in PGR and GREB1 (Supplementary Figure S4) .
In order to address this further, chromatin immunoprecipitation was performed in MCF7-LTED cells. AZD5363 caused a reduction in recruitment of ER, AIB1 and CBP to the EREs on the TFF1, GREB1 and PGR promoters (Fig. 4C) , supporting the impact of AZD5363 on ER- 
Combination of AZD5363 and fulvestrant in the luminal BC xenograft HBCx22OvaR
A high degree of redundancy in the kinase networks and cross-talk with ER is well documented (23), suggesting destruction of ER with fulvestrant may be a better strategy than antagonism with tamoxifen or blockade of estrogen biosynthesis with an AI. Therefore, we assessed the combination of fulvestrant and AZD5363 compared with monotherapy in a patient derived luminal BC xenograft HBCx22OvaR modeling acquired resistance to E-deprivation (22) (Fig. 5 ).
Treatments were well tolerated. Fulvestrant monotherapy treatment caused a modest but nonsignificant reduction in tumour growth compared with the vehicle control group (30% inhibition, p=0.11). Continuous dosing of AZD5363 at 50mg/kg bid resulted in a significant reduction in tumour growth (57% inhibition, p=5.0E-03), compared with vehicle control. Combination of fulvestrant with AZD5363 resulted in almost complete inhibition of tumour growth (80% inhibition p< 1E-05) compared to vehicle control. The combination dosing was significantly more active than AZD5363 and fulvestrant monotherapy groups (p=3.75E-03 and 6.3E-04, respectively) (Fig. 5A) . After 90-days of treatment, the therapies were withdrawn and tumour volume assessed to establish the efficacy of the combination in delaying tumour progression. (Fig. 5B) , whilst the combination of AZD5363 plus fulvestrant showed sustained anti-tunour effect even after 50 days post-cessation of treatment.
In order to assess dynamic changes in the PI3K/AKT/mTOR, ER, apoptotic and cell cycle pathways, a second xenograft experiment was carried out to study tumour pharmacodynamics.
HBCx22OvaR were treated for 4-days with the combinations indicated and samples resected 2 and 4-hours post-dosing of AZD5363. As expected, western blot analysis showed significant increases in pAKT (S473) and pAKT (T308) and decreases in pPRAS40 in response to AZD5363. Two-hours post-treatment with AZD5363 showed a significant rise in PGR expression compared to vehicle control and was negated by the addition of fulvestrant (Fig. 5C ).
In order to assess the effect of AZD5363 on ER-mediated transcription, we used Fluidigm analysis of several ER-dependent target genes (Fig. 5D ). Fulvestrant caused a significant reduction in expression of the majority of the genes selected whilst AZD5363 showed a trend towards an increase. The combination of fulvestrant plus AZD5363 negated this rise. Four-hours post-therapy showed a significant rise in ER-regulated genes in response to AZD5363 monotherapy and addition of fulvestrant did not suppress this effect with the exception of TFF1.
Analysis of CCND1 showed a decrease in response to fulvestrant and the combination with AZD5363. However, 4-hours post-treatment showed a rise in expression. In contrast, CCNG2, which blocks cell cycle entry and is negatively regulated by E-bound-ER and activated PI3K (24,25), was increased in all AZD5363 treatment groups, indicative of cell cycle arrest.
Furthermore, AZD5363 caused increases in CASP9 and BMF expression indicating of a rise in apoptosis (Fig. 5D) . The combination of AZD5363 with endocrine therapy showed the greatest efficacy in both ER+, endocrine sensitive and resistant cell lines, most notably those containing activating mutations in PIK3CA and/or loss of PTEN function (Fig.1) . In contrast, HCC1428, which are wild-type (wt) for both genes, were resistant to AKT inhibition (GI 50 > 10000nM). The combination of AZD5363 with fulvestrant provided the greatest combination effect, which was later confirmed in a patient derived xenograft model. Nonetheless, the combination of AZD5363 with an AI was also highly effective. Moreover, ZR75-LTED and T47D-LTED, which have suppressed expression of ER compared to their parental cells, were the most sensitive to the antiproliferative effects of single agent AZD5363, with GI 50 values less than 100nM. It is noteworthy, that PIK3CA mutation may not be the only governing feature of sensitivity to AKT inhibition. For instance, both MCF7 and T47D cells and their derivatives express mutant PIK3CA and wt-PTEN, yet T47D were at least 2-fold more sensitive than MCF7, and this is most pronounced when comparing T47D-LTED with MCF7-LTED, where there is a 5-fold difference in sensitivity.
Furthermore, ZR75, which are wt-PIK3CA and PTEN null, are 5-fold less sensitive than ZR75-LTED, suggesting that whilst mutation within the pathway may delineate sensitivity in some circumstances, cell context remains a defining feature. Previous studies have shown that AKT can phosphorylate ER at serine 167 in a ligand independent manner and is associated with resistance to endocrine therapy (10,19); furthermore, elevated AKT has been associated with an altered ER transcriptional program (13) . In this current study, we provided further support for these observations and showed that inhibition of deleterious effects of the inactivation of PI3K or AKT (32) . The IGF1 signaling pathway, which encompasses IGF1R, IRS2 and FOXO3 was also significantly upregulated. Previous studies have shown that upregulation of IGF1R maintains PI3K activity and PIP3 formation, to counteract the inhibition of AKT which could potentially reduce the potency of AZD5363, via a FOXO dependent transcriptional mechanism (17).
RAR signalling was also associated with inhibition of AKT activity. RAR transactivation is suppressed by phosphorylation via AKT (33) . Of note, RAR-alpha (α) is required for efficient ER-mediated transcription and cell proliferation (34) . Assessment of the effect of AZD5363 on ER-mediated transactivation using an artificial reporter construct showed suppression of transactivation. However, assessment of transcript levels of several endogenous E2-regulated genes particularly in the T47D and TamR cell line as well as in our PDX model showed increases in TFF1 and GREB1 expression, in keeping with previous studies with a dual mTOR/PI3K inhibitor (35) . Of note, assessment of genes within the RAR signalling pathways showed increases in expression of CDK7, which has previously been shown to phosphorylate and activate both ER (36) and RARα (37) . Furthermore, high intratumoral RARα protein levels correlate with reduced relapse free survival in ER+ patients treated with neoadjuvant tamoxifen (38) . Taken together, activation of RAR as a result of AKT inhibition may potentiate ER-activity in certain settings.
ERK5 signaling pathway was significantly upregulated in response to AZD5363. ERK5, similar to ERK1/2, regulates EGF-induced cell proliferation and is known to cross talk with ERBB2 and PDGFR. Both of pathways were also elevated in response to AZD5363. ERK5 is also capable of phosphorylating the ERK1/2 substrates MYC and AP1 (39) . Moreover, ILK, HIF1 and VEGF 
parvin, which is lost in metastastic BC (40) , leads to an upregulation of ILK/AKT mediated signalling resulting in increased HIF1α and VEGF (41) . Both HIF1α and VEGF contain internal ribosome entry sites (IRES), located in their 5' UTRs, allowing cap independent translation, bypassing the requirement for mTOR/4EBP1 signaling (42) . This may provide a survival mechanism in response to chronic treatment with AZD5363. Of particular interest, MYC expression was identified as a potential driver in six of the upregulated pathways in response to AZD5363. MYC activity has been shown to abrogate response to mTOR inhibition in prostate cancer via its interaction and upregulation of 4EBP1 (43) . Notably, 4EBP1 expression did not change in response to AZD5363 in our PDX model. 
